Marshall Wace’s Relmada Therapeutics RLMD Stock Holding History

Marshall Wace’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.5M	Sell	2,246,839 -2,234,767	-50%	-$15.6M	0.01%	834
2026 Q1	$31.2M	Buy	4,481,606 +1,291,944	+41%	+$6.11M	0.03%	543
2025 Q4	$15.4M	Buy	3,189,662 +2,917,609	+1,072%	+$9.78M	0.01%	724
2025 Q3	$547K	Buy	272,053 +117,485	+76%	+$113K	﹤0.01%	2196
2025 Q2	$92.7K	Buy	+154,568	New	+$79.3K	﹤0.01%	2551
2024 Q4	–	Sell	-50,570	Closed	-$164K	–	2940
2024 Q3	$164K	Sell	50,570 -106,049	-68%	-$343K	﹤0.01%	2318
2024 Q2	$470K	Sell	156,619 -51,251	-25%	-$185K	﹤0.01%	1988
2024 Q1	$967K	Buy	207,870 +54,345	+35%	+$262K	﹤0.01%	1665
2023 Q4	$636K	Buy	+153,525	New	+$455K	﹤0.01%	1629
2022 Q4	–	Sell	-96,254	Closed	-$3.56M	–	3348
2022 Q3	$3.56M	Buy	+96,254	New	+$2.67M	0.01%	1624

Other funds holding RLMD

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace's RLMD Position: Q2 2026 in Review

Marshall Wace reduced its Relmada Therapeutics (RLMD) stake by 50% in Q2 2026, selling an estimated $15.6M and leaving 2,246,839 shares worth $15.5M. The position accounts for 0.01% of the portfolio, ranked #834.

Marshall Wace first reported a position in RLMD in Q3 2022 and has held it in 10 quarters since. The position peaked at $31.2M in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

Marshall Wace held 2,246,839 shares of Relmada Therapeutics worth $15.5M as of Q2 2026.
Marshall Wace sold 2,234,767 Relmada Therapeutics shares in Q2 2026, an estimated $15.6M.
Relmada Therapeutics made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #834 holding.
Marshall Wace first reported a position in Relmada Therapeutics in Q3 2022 and has held it in 10 quarters since.
Marshall Wace's Relmada Therapeutics position peaked at $31.2M in Q1 2026.
126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.